Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis

Junichi Kodama, Aiko Sasaki, Satoko Masahiro, Noriko Seki, Tomoyuki Kusumoto, Keiichiro Nakamura, Atsushi Hongo, Yuji Hiramatsu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Few reports delineate the pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in hemodialysis (HD) patients with epithelial ovarian cancer. However, the optimal carboplatin dose and the timing of HD have yet to be elucidated. We presented a case of an advanced-stage epithelial ovarian cancer patient with chronic renal failure requiring HD. After 4 courses of combination chemotherapy consisting of paclitaxel and carboplatin, a partial response was obtained; therefore, she underwent interval debulking surgery. Paclitaxel was administered for 3 h at a dose of 150 mg/m2, and carboplatin was administered for 1 h at a dose of 4-7 area under the concentration/time curve (AUC), which was calculated by the Calvert formula. HD was initiated 24 h after the start of administration of carboplatin and performed for a period of 3 h. Pharmacokinetic studies showed that the AUCs of free platinum and paclitaxel were 3.48-5.55 mgmin/ ml and 13.5 μgh/ml, respectively. Combination chemotherapy consisting of paclitaxel and carboplatin is a feasible approach to improving the treatment outcome of epithelial ovarian cancer patients with chronic renal failure requiring HD. The measurement of free platinum is useful in determining the optimal dose of carboplatin in order to obtain an adequate AUC. Determining the dose of carboplatin according to the Calvert formula and initiating HD after 24 h would ensure a favorable therapeutic effect with limited side effects.

Original languageEnglish
Pages (from-to)511-513
Number of pages3
JournalOncology Letters
Volume1
Issue number3
DOIs
Publication statusPublished - May 2010

Fingerprint

Carboplatin
Paclitaxel
Combination Drug Therapy
Renal Dialysis
Pharmacokinetics
Platinum
Chronic Kidney Failure
Ovarian epithelial cancer
Therapeutic Uses
Area Under Curve

Keywords

  • Carboplatin
  • Epithelial ovarian cancer
  • Hemodialysis
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. / Kodama, Junichi; Sasaki, Aiko; Masahiro, Satoko; Seki, Noriko; Kusumoto, Tomoyuki; Nakamura, Keiichiro; Hongo, Atsushi; Hiramatsu, Yuji.

In: Oncology Letters, Vol. 1, No. 3, 05.2010, p. 511-513.

Research output: Contribution to journalArticle

Kodama, Junichi ; Sasaki, Aiko ; Masahiro, Satoko ; Seki, Noriko ; Kusumoto, Tomoyuki ; Nakamura, Keiichiro ; Hongo, Atsushi ; Hiramatsu, Yuji. / Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. In: Oncology Letters. 2010 ; Vol. 1, No. 3. pp. 511-513.
@article{856b500ece024587aedc67a4802313e1,
title = "Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis",
abstract = "Few reports delineate the pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in hemodialysis (HD) patients with epithelial ovarian cancer. However, the optimal carboplatin dose and the timing of HD have yet to be elucidated. We presented a case of an advanced-stage epithelial ovarian cancer patient with chronic renal failure requiring HD. After 4 courses of combination chemotherapy consisting of paclitaxel and carboplatin, a partial response was obtained; therefore, she underwent interval debulking surgery. Paclitaxel was administered for 3 h at a dose of 150 mg/m2, and carboplatin was administered for 1 h at a dose of 4-7 area under the concentration/time curve (AUC), which was calculated by the Calvert formula. HD was initiated 24 h after the start of administration of carboplatin and performed for a period of 3 h. Pharmacokinetic studies showed that the AUCs of free platinum and paclitaxel were 3.48-5.55 mgmin/ ml and 13.5 μgh/ml, respectively. Combination chemotherapy consisting of paclitaxel and carboplatin is a feasible approach to improving the treatment outcome of epithelial ovarian cancer patients with chronic renal failure requiring HD. The measurement of free platinum is useful in determining the optimal dose of carboplatin in order to obtain an adequate AUC. Determining the dose of carboplatin according to the Calvert formula and initiating HD after 24 h would ensure a favorable therapeutic effect with limited side effects.",
keywords = "Carboplatin, Epithelial ovarian cancer, Hemodialysis, Paclitaxel",
author = "Junichi Kodama and Aiko Sasaki and Satoko Masahiro and Noriko Seki and Tomoyuki Kusumoto and Keiichiro Nakamura and Atsushi Hongo and Yuji Hiramatsu",
year = "2010",
month = "5",
doi = "10.3892/ol_00000090",
language = "English",
volume = "1",
pages = "511--513",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis

AU - Kodama, Junichi

AU - Sasaki, Aiko

AU - Masahiro, Satoko

AU - Seki, Noriko

AU - Kusumoto, Tomoyuki

AU - Nakamura, Keiichiro

AU - Hongo, Atsushi

AU - Hiramatsu, Yuji

PY - 2010/5

Y1 - 2010/5

N2 - Few reports delineate the pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in hemodialysis (HD) patients with epithelial ovarian cancer. However, the optimal carboplatin dose and the timing of HD have yet to be elucidated. We presented a case of an advanced-stage epithelial ovarian cancer patient with chronic renal failure requiring HD. After 4 courses of combination chemotherapy consisting of paclitaxel and carboplatin, a partial response was obtained; therefore, she underwent interval debulking surgery. Paclitaxel was administered for 3 h at a dose of 150 mg/m2, and carboplatin was administered for 1 h at a dose of 4-7 area under the concentration/time curve (AUC), which was calculated by the Calvert formula. HD was initiated 24 h after the start of administration of carboplatin and performed for a period of 3 h. Pharmacokinetic studies showed that the AUCs of free platinum and paclitaxel were 3.48-5.55 mgmin/ ml and 13.5 μgh/ml, respectively. Combination chemotherapy consisting of paclitaxel and carboplatin is a feasible approach to improving the treatment outcome of epithelial ovarian cancer patients with chronic renal failure requiring HD. The measurement of free platinum is useful in determining the optimal dose of carboplatin in order to obtain an adequate AUC. Determining the dose of carboplatin according to the Calvert formula and initiating HD after 24 h would ensure a favorable therapeutic effect with limited side effects.

AB - Few reports delineate the pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in hemodialysis (HD) patients with epithelial ovarian cancer. However, the optimal carboplatin dose and the timing of HD have yet to be elucidated. We presented a case of an advanced-stage epithelial ovarian cancer patient with chronic renal failure requiring HD. After 4 courses of combination chemotherapy consisting of paclitaxel and carboplatin, a partial response was obtained; therefore, she underwent interval debulking surgery. Paclitaxel was administered for 3 h at a dose of 150 mg/m2, and carboplatin was administered for 1 h at a dose of 4-7 area under the concentration/time curve (AUC), which was calculated by the Calvert formula. HD was initiated 24 h after the start of administration of carboplatin and performed for a period of 3 h. Pharmacokinetic studies showed that the AUCs of free platinum and paclitaxel were 3.48-5.55 mgmin/ ml and 13.5 μgh/ml, respectively. Combination chemotherapy consisting of paclitaxel and carboplatin is a feasible approach to improving the treatment outcome of epithelial ovarian cancer patients with chronic renal failure requiring HD. The measurement of free platinum is useful in determining the optimal dose of carboplatin in order to obtain an adequate AUC. Determining the dose of carboplatin according to the Calvert formula and initiating HD after 24 h would ensure a favorable therapeutic effect with limited side effects.

KW - Carboplatin

KW - Epithelial ovarian cancer

KW - Hemodialysis

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=77955721461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955721461&partnerID=8YFLogxK

U2 - 10.3892/ol_00000090

DO - 10.3892/ol_00000090

M3 - Article

VL - 1

SP - 511

EP - 513

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -